Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients

Clinical Nephrology

Volumn 75, Issue 1, 2011, Pages 49-58

  Abe, M ^a   Okada, K ^a   Soma, M ^a   Matsumoto, K ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Erythropoietin; Hemodialysis; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; HEMOGLOBIN; HEMOGLOBIN A1C; INTERLEUKIN 6; LEPTIN; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; COMORBIDITY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; STATISTICAL ANALYSIS;

ADIPONECTIN; AGED; ANEMIA; BIOLOGICAL MARKERS; CYTOKINES; DIABETES MELLITUS, TYPE 2; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; JAPAN; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79251518102     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CNP75049     Document Type: Article

References (30)

1. Shinohara K, Shoji T, Emoto M et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 1894-1900.
2. Spaia S, Pangalos M, Askepidis N et al. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron. 2000; 84: 320-325.
3. Mak RHK. Renal disease, insulin resistance and glucose intolerance. Diabetes Rev. 1994; 2: 19-28.
4. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005; 67: 1216-1233.
5. Gonzalez NJF, Fernandez MC. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol.2008; 19: 433-442.
6. Zimmermann J, Herrlinger S, Pruy A, Metzeger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.
7. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 134-141. (Pubitemid 34042020)
8. Tsubakihara Y, Nishi S, Akiba T et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Thera Apher Dial. 2010; 14: 240-275.
9. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352: 1011-1023.
10. Eschbach JW. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol. 2002; 13: 1412-1414.
11. El-Achkar TM, Ohmit SE, McCullough PA et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005; 67: 1483-1488.
12. Thomas MC, Tsalamandris C, Macisaac R et al. Functional erythropoietin deficiency in patients with type 2 diabetes and anaemia. Diabet Med. 2006; 23: 502-509.
13. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91.
14. Shoji T Shinohara K, Hastuda S et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism. 2005; 54: 330-334.
15. Pittas AG, Nandini AJ, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004; 89: 447-452.
16. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16: 2134-2140.
17. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994; 45: 890-896.
18. Shoji T, Nishizawa Y, Emoto M et al. Renal function and insulin resistance as determinants of plasma leptin levels in patients with NIDDM. Diabetologia. 1997; 40: 676-679.
19. Kalantar-Zadeh K, Ikizler A, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003; 42: 864-881.
20. Filho RP, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant. 2002; 17: 28-31.
21. Tonbul HZ, Demir M, Altintepe L et al. Malnutrition-inflammation- atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Renal Failure. 2006; 28: 287-294.
22. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu M. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A5-year prospective study. Nephron Clin Pract. 2008; 108: 99-105.
23. Stenvinkel P, Alvestrand A. Inflammation is end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002; 15: 329-337.
24. Barany P, Divino FJC, Bergstrome J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 29: 565-568.
25. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acutephase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33: 63-72.
26. Sitter T, Berger A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000; 15: 1207-1211.
27. Kalantar-Zadeh K, McAllister C, Lehn R, Lee G, Nissenson A, Kopple J. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003; 42: 761-773.
28. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998; 18: 555-559.
29. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337-1343.
30. Sit D, Kadiroglu AK, Yilmaz ME. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Renal Failure. 2005; 27: 403-407.